- Thalidomide as an immunomodulatory agent1999 | Faculty of Pharmacy in Hradec Králové
- Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone2016 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Current Immunotherapy Approaches in Non-Hodgkin Lymphomas2020 | First Faculty of Medicine
- Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy-free Era2019 | First Faculty of Medicine
- Depresion and Multiple Sclerosis2003 | First Faculty of Medicine
- Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Long-term combination therapy of ustekinumab and dapsone in a patient with psoriasis and dermatitis herpetiformis Duhring2012 | Third Faculty of Medicine
- 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus2019 | First Faculty of Medicine
- BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis2011 | First Faculty of Medicine
- BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis2011 | Second Faculty of Medicine
- Hpma-based copolymers carrying stat3 inhibitor cucurbitacin-d as stimulus-sensitive nanomedicines for oncotherapy2021 | Central Library of Charles University
- Pathogenesis, immunology, and immune-targeted management of the multisystem inflammatory syndrome in children (MIS-C) or pediatric inflammatory multisystem syndrome (PIMS): EAACI Position Paper2023 | First Faculty of Medicine, Second Faculty of Medicine
- Management of multiple sclerosis patients in central European countries: current needs and potential solutions2018 | First Faculty of Medicine
- AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma2019 | First Faculty of Medicine
- Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial2020 | First Faculty of Medicine
- ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma2021 | Faculty of Medicine in Hradec Králové, Central Library of Charles University
- Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study2021 | First Faculty of Medicine
- Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study2020 | Faculty of Medicine in Hradec Králové